The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION&#174; medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage

AVA-6103 - Avacta

Curtis Rink; Tom Clough; Ellen Watts; Folake Orafidiya; Marine Houee; Cindy Tong; Victoria Juskaite; Michelle Morrow; David Jones; Francis Wilson

Mar 26, 2025